S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:DNLI

Denali Therapeutics Competitors

$61.04
+2.34 (+3.99 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$55.61
Now: $61.04
$61.10
50-Day Range
$58.70
MA: $69.93
$81.53
52-Week Range
$12.39
Now: $61.04
$93.94
Volume643,073 shs
Average Volume662,194 shs
Market Capitalization$7.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta2

Competitors

Denali Therapeutics (NASDAQ:DNLI) Vs. SGEN, BNTX, TECH, ARGX, NVAX, and QGEN

Should you be buying DNLI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Denali Therapeutics, including Seagen (SGEN), BioNTech (BNTX), Bio-Techne (TECH), argenx (ARGX), Novavax (NVAX), and QIAGEN (QGEN).

Denali Therapeutics (NASDAQ:DNLI) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Comparatively, 31.1% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Denali Therapeutics and Seagen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49
Seagen$916.71 million29.52$-158,650,000.00($1.33)-112.29

Seagen has higher revenue and earnings than Denali Therapeutics. Seagen is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Denali Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Denali Therapeutics and Seagen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01902.90
Seagen151112.67

Denali Therapeutics presently has a consensus price target of $65.1111, suggesting a potential upside of 6.67%. Seagen has a consensus price target of $188.4615, suggesting a potential upside of 26.19%. Given Seagen's higher probable upside, analysts clearly believe Seagen is more favorable than Denali Therapeutics.

Profitability

This table compares Denali Therapeutics and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
Seagen25.34%20.46%16.67%

Summary

Seagen beats Denali Therapeutics on 12 of the 15 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Profitability

This table compares Denali Therapeutics and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Denali Therapeutics-968.59%-39.19%-30.71%
BioNTech-250.12%-66.72%-41.73%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Denali Therapeutics and BioNTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Denali Therapeutics01902.90
BioNTech04302.43

Denali Therapeutics presently has a consensus price target of $65.1111, suggesting a potential upside of 6.67%. BioNTech has a consensus price target of $102.75, suggesting a potential upside of 6.81%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Denali Therapeutics.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 10.8% of BioNTech shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Denali Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, indicating that its stock price is 274% less volatile than the S&P 500.

Valuation and Earnings

This table compares Denali Therapeutics and BioNTech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49
BioNTech$121.63 million190.44$-200,540,000.00($0.95)-101.26

Denali Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Denali Therapeutics beats BioNTech on 10 of the 14 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Bio-Techne and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Denali Therapeutics-968.59%-39.19%-30.71%

Analyst Recommendations

This is a breakdown of current ratings for Bio-Techne and Denali Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne04602.60
Denali Therapeutics01902.90

Bio-Techne currently has a consensus target price of $352.30, suggesting a potential downside of 1.10%. Denali Therapeutics has a consensus target price of $65.1111, suggesting a potential upside of 6.67%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Bio-Techne.

Insider & Institutional Ownership

93.8% of Bio-Techne shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 3.8% of Bio-Techne shares are held by company insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

Earnings & Valuation

This table compares Bio-Techne and Denali Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million18.71$229.30 million$3.8692.28
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49

Bio-Techne has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats Denali Therapeutics on 8 of the 14 factors compared between the two stocks.

argenx (NASDAQ:ARGX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares argenx and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Denali Therapeutics-968.59%-39.19%-30.71%

Analyst Recommendations

This is a breakdown of current ratings for argenx and Denali Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071002.59
Denali Therapeutics01902.90

argenx currently has a consensus target price of $292.25, suggesting a potential upside of 0.86%. Denali Therapeutics has a consensus target price of $65.1111, suggesting a potential upside of 6.67%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than argenx.

Insider & Institutional Ownership

54.2% of argenx shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

argenx has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

Earnings & Valuation

This table compares argenx and Denali Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million175.48$-182,520,000.00($4.73)-61.26
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49

argenx has higher revenue and earnings than Denali Therapeutics. argenx is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Denali Therapeutics beats argenx on 8 of the 14 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares Novavax and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Denali Therapeutics-968.59%-39.19%-30.71%

Analyst Recommendations

This is a breakdown of current ratings for Novavax and Denali Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax10602.71
Denali Therapeutics01902.90

Novavax currently has a consensus target price of $213.9286, suggesting a potential upside of 22.36%. Denali Therapeutics has a consensus target price of $65.1111, suggesting a potential upside of 6.67%. Given Novavax's higher probable upside, equities research analysts clearly believe Novavax is more favorable than Denali Therapeutics.

Insider & Institutional Ownership

49.9% of Novavax shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

Earnings & Valuation

This table compares Novavax and Denali Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million596.48$-132,690,000.00($5.80)-30.14
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49

Novavax has higher earnings, but lower revenue than Denali Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Denali Therapeutics beats Novavax on 9 of the 14 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Profitability

This table compares QIAGEN and Denali Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Denali Therapeutics-968.59%-39.19%-30.71%

Analyst Recommendations

This is a breakdown of current ratings for QIAGEN and Denali Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN16902.50
Denali Therapeutics01902.90

QIAGEN currently has a consensus target price of $56.3689, suggesting a potential upside of 18.62%. Denali Therapeutics has a consensus target price of $65.1111, suggesting a potential upside of 6.67%. Given QIAGEN's higher probable upside, equities research analysts clearly believe QIAGEN is more favorable than Denali Therapeutics.

Insider & Institutional Ownership

43.6% of QIAGEN shares are held by institutional investors. Comparatively, 68.2% of Denali Therapeutics shares are held by institutional investors. 9.0% of QIAGEN shares are held by company insiders. Comparatively, 19.3% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

QIAGEN has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

Earnings & Valuation

This table compares QIAGEN and Denali Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.09$-41,460,000.00$1.4333.23
Denali Therapeutics$26.68 million276.79$-197,610,000.00($2.07)-29.49

QIAGEN has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Summary

QIAGEN beats Denali Therapeutics on 8 of the 13 factors compared between the two stocks.


Denali Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Seagen logo
SGEN
Seagen
1.7$149.35+2.6%$27.06 billion$916.71 million58.80Insider Selling
Decrease in Short Interest
Gap Up
BioNTech logo
BNTX
BioNTech
0.9$96.20+1.1%$23.16 billion$121.63 million-48.10Decrease in Short Interest
Bio-Techne logo
TECH
Bio-Techne
1.8$356.21+2.3%$13.82 billion$738.69 million56.99Gap Up
argenx logo
ARGX
argenx
1.1$289.75+0.5%$13.72 billion$78.17 million-61.26Earnings Announcement
Analyst Report
News Coverage
Novavax logo
NVAX
Novavax
1.4$174.84+9.6%$11.13 billion$18.66 million-33.49Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
QIAGEN logo
QGEN
QIAGEN
1.7$47.52+0.1%$10.82 billion$1.53 billion58.67
Repligen logo
RGEN
Repligen
1.5$186.19+1.6%$10.20 billion$270.24 million227.06Analyst Report
Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.23+0.3%$8.76 billion$788.10 million100.25Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$114.65+0.7%$8.65 billion$289.59 million-35.17Analyst Report
High Trading Volume
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$83.65+0.6%$7.84 billion$10.68 million-45.46Analyst Report
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.4$127.79+0.1%$7.74 billion$73.99 million-49.34Analyst Report
High Trading Volume
News Coverage
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.23+3.4%$5.88 billion$85.07 million-44.45Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Vir Biotechnology logo
VIR
Vir Biotechnology
1.6$45.18+12.2%$5.78 billion$8.09 million-19.14Analyst Report
News Coverage
Gap Up
Twist Bioscience logo
TWST
Twist Bioscience
1.4$117.55+0.8%$5.72 billion$90.10 million-31.35High Trading Volume
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.91+1.2%$5.53 billion$195.99 million255.69
Kodiak Sciences logo
KOD
Kodiak Sciences
1.3$120.49+7.3%$5.40 billionN/A-51.94Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$34.00+4.6%$4.78 billionN/A-15.96Analyst Revision
Gap Up
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$32.36+1.8%$4.76 billionN/A-16.85Analyst Upgrade
High Trading Volume
China Biologic Products logo
CBPO
China Biologic Products
0.8$117.76+0.3%$4.64 billion$503.70 million32.89Upcoming Earnings
Increase in Short Interest
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.60+1.2%$4.21 billion$20,000.00-5.17Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.6$74.40+6.9%$3.64 billionN/A-42.76Analyst Report
High Trading Volume
Gap Up
RLAY
Relay Therapeutics
1.8$37.39+7.0%$3.36 billionN/A0.00Gap Down
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$45.50+6.7%$3.02 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
NantKwest logo
NK
NantKwest
1.1$26.80+3.9%$2.92 billion$40,000.00-37.75Decrease in Short Interest
Gap Down
Editas Medicine logo
EDIT
Editas Medicine
1.4$41.63+3.1%$2.80 billion$20.53 million-23.93Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.37+3.7%$2.79 billion$125.57 million-37.06Earnings Announcement
Analyst Report
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.88+0.8%$2.49 billion$31.43 million-6.08Analyst Revision
News Coverage
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$48.18+4.8%$2.14 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
AlloVir logo
ALVR
AlloVir
1.4$30.52+13.1%$1.99 billionN/A0.00Insider Selling
High Trading Volume
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Vericel logo
VCEL
Vericel
1.5$42.51+4.9%$1.95 billion$117.85 million-4,251,000.00Analyst Report
Analyst Revision
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.68+2.6%$1.93 billion$44.67 million-2.61Analyst Report
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$53.53+5.5%$1.80 billion$20.49 million-22.21Upcoming Earnings
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63+6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23+4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74+2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31+8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74+1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93+1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87+1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
Alector logo
ALEC
Alector
1.3$17.07+4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07+1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51+3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76+0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83+3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99+4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36+20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12+1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17+0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.